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OBJECTIVE — The present study characterizes mannose-binding lectin (MBL), an activator
of the complement system and thereby important for inﬂammatory activation, in patients with
diabetes and myocardial infarction.
RESEARCH DESIGN AND METHODS — Serum (S)-MBL was determined at hospital
admissionin387patientswithtype2diabetes(medianage70years;68%male)withmyocardial
infarction, and genotyping was performed in 287 patients. Cardiovascular events (cardiovascu-
lar mortality and nonfatal myocardial infarction or stroke) were recorded during 2.5 years.
RESULTS — Median S-MBL was 1,212 g/l (interquartile range [IQR] 346–2,681 g/l). Of
the subjects, 54% in the geno- and phenotype subgroup had a high-coding MBL genotype
(median S-MBL  2,658 g/l [IQR 1,715–3,829]) and 46% a low-coding MBL genotype (373
g/l [100–765]). S-MBL did not correlate with age, BMI, creatinine clearance, glucose, or A1C.
Cardiovascular events occurred in 136 (35%) patients. S-MBL did not predict events in univa-
riable analyses (hazard ratio 0.93 [95% CI 0.85–1.01]; P  0.09). In unadjusted analyses, the
risk of events was lower in patients with a high genotype and S-MBL above the median for their
genotype(0.49[0.26–0.92];P0.026)thanforpatientswithalowgenotypeandS-MBLbelow
themedianfortheirgenotype.Thepredictioncapacityofthegeno-andphenotypemodelwasof
borderline signiﬁcance in adjusted Cox regression.
CONCLUSIONS — Patients with type 2 diabetes and myocardial infarction have MBL ge-
notypes that are similar to those known in the general population. The combination of a low-
coding MBL genotype with a low S-MBL appears to be prognostically unfavorable, but the
association is blunted by traditional risk markers.
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M
acrovascular complications, not
the least is myocardial infarction,
are leading causes of death in pa-
tients with type 2 diabetes. An improved
understanding of pathophysiological
mechanisms is a prerequisite for the de-
velopment of new treatment targets.
Chronic, low-grade inﬂammation is a
componentinthedevelopmentofathero-
sclerosis and coronary artery disease (1).
There is evidence of increased inﬂamma-
tory activation and downstream markers
of inﬂammation, e.g., C-reactive protein,
predict an increased risk of cardiovascu-
larmortalityandmorbidity(1).Toenable
a successful modulation of disease pro-
gression,itis,however,likelythattheear-
lier stages of the inﬂammatory process
should be targeted.
Mannose-binding lectin (MBL) is a
patternrecognitionmoleculeoftheinnate
immune system that has attracted interest
in the context of cardiovascular disease
(2).MBLactivatesthelectinpathway,one
of three (classic, lectin, or alternative)
arms, which initiates the complement
cascade (3). Although MBL acts as an
acute-phasereactant,circulatinglevelsre-
main stable over time, only increasing
two- to threefold during stress (3). How-
ever, genetic regulation accounts for a
considerable variation in MBL concentra-
tionamongindividuals.MBLdeﬁciencyis
associated with autoimmune, inﬂamma-
tory, and vascular diseases (4). Informa-
tion on a potential link between MBL and
cardiovascular complications is contra-
dictory. MBL levels were higher among
patients with acute coronary syndromes
than among control subjects in a recent
study (5) and in another study compris-
ing 890 patients with ST-segment
myocardial infarction undergoing percu-
taneouscoronaryintervention,functional
deﬁciency of complement MBL, deﬁned
as 100 ng/ml, was associated with re-
duced mortality but not with a decreased
risk of the combined end points of death
and shock or death, shock, and conges-
tiveheartfailure(6).Incontrast,lowMBL
levels and MBL2 genotypes have been
linked to atherosclerosis (7,8), and indi-
vidualswithMBLdeﬁciencyhaveahigher
risk of coronary artery disease (9,10).
The aim of the present report was to
characterize MBL geno- and phenotypes
in patients with type 2 diabetes and acute
myocardialinfarction(AMI).Asecondary
aim was to test the hypothesis that this
informationmaybeusefulasaprognostic
marker in such patients.
RESEARCH DESIGN AND
METHODS— The Diabetes Mellitus
Insulin-Glucose Infusion in Acute Myo-
cardial Infarction (DIGAMI 2) trial com-
pared three different management
strategies in patients with type 2 diabetes
andsuspectedAMI.Anextensivedescrip-
tion of the study design has been pre-
sented elsewhere (11). In short, 1,253
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three study arms receiving 1) a 24-h insu-
lin-glucose infusion, followed by subcu-
taneous insulin-based long-term glucose
control (group 1, n  474); 2) the same
initial treatment, followed by glucose-
lowering treatment according to local
practice(group2,n473);or3)glucose-
lowering treatment according to local
practice(group3,n306).Therewasno
signiﬁcant difference in total mortality or
nonfatal myocardial infarction and stroke
during the median follow-up period of
2.1 years. This allowed the possibility of
combiningallDIGAMI2patientsintoone
cohort suitable for post hoc epidemiolog-
ical analyses disregarding randomized
group belonging. The present study con-
sists of 387 participants in a biochemistry
substudy, in which serum (S) MBL was
determined at hospital admission. In 287
of them, samples were available for both
S-MBL and MBL2 genotyping.
Investigations
Samples for assessments of the following
variables were obtained as soon as possi-
ble after hospital admission: electrolytes,
serum creatinine, blood lipids, glucose
(millimoles per liter in whole blood),
A1C, and S-MBL. Samples for genetic
analyses were obtained at the time of hos-
pital discharge. A1C was analyzed by
high-performance liquid chromatogra-
phy with an upper normal limit of 5.3%.
Creatinine clearance (milliliters per min)
was calculated using the Cockroft-Gault
method. S-MBL levels were measured us-
ing an in-house, time-resolved immun-
oﬂuorometric assay (12). The lower
detection level was 10 g/l, and the intra-
assay and inter-assay coefﬁcients of vari-
ation were 10%.
Afulldescriptionofthegenotypingof
the patients is found in the supplemen-
tary data (available in an online appen-
dix at http://care.diabetesjournals.org/
cgi/content/full/dc10-0903/DC1). In short,
DNA was extracted from whole blood and
analyzedusingreal-timePCRwithTaqMan
single nucleotide genotyping assays (Ap-
pliedBiosystems,FosterCity,CA)(13–15).
The presence of one of the three
structural mutations in the MBL2 gene,
located at 10q21.1, the D, B, and C vari-
ants (designated as “O”), signiﬁcantly re-
duces circulating MBL. Of the three
known promoter polymorphisms, only
the X/Y polymorphism inﬂuences S-MBL,
causing reduced MBL levels (5). In the
present report, genotypes were catego-
rized according to polymorphisms in the
MBL2 gene as AA (wild-type), AO (het-
erozygote), or OO (homozygote). After
the addition of information on the pro-
moterregion,genotypeswereclassiﬁedas
high (including all AA with the exclusion
of homozygotes for the X promotor) or
low, as determined previously by Hansen
et al. (16).
A composite of cardiovascular death,
reinfarction, or stroke, adjudicated by an
independent committee composed of ex-
perienced cardiologists, served as the pri-
mary end point.
Statistical methods
Continuous variables are presented as
median and interquartile range (IQR),
unless otherwise stated. The Wilcoxon
Mann-Whitneytestwasusedtostudydif-
ferences between groups of patients strat-
iﬁed by dichotomous variables, and the
association between continuous variables
was assessed by means of Spearman rank
correlation. The Jonckheere-Terpstra test
was used to compare differences between
genotypesandcombinationsofgeno-and
phenotypes. The relationships between
S-MBL and age, sex, BMI, previous myo-
cardial infarction, heart failure, hyperten-
sion, creatinine clearance, B-glucose, and
A1C at admission were studied by regres-
sion analyses.
The relationship between S-MBL and
the primary end point was assessed using
Cox proportional hazards regression and
presented as hazard ratios (HR) and 95%
CIs. Because of skewed distribution, S-
MBLwaslog-transformedbeforeanalysis.
No model building was performed in the
principal analysis. For the outcome anal-
ysis, S-MBL was dichotomized below or
above a level of 1,000 g/l according to
previous ﬁndings, demonstrating that
this cutoff level has high sensitivity and
speciﬁcity for risk prediction (10,17). Pa-
tients were also classiﬁed according to
their genotypes in relation to the median
S-MBL concentration for the respective
genotype: high/above indicates high ge-
notype with S-MBL above the median for
this genotype; high/below indicates high
genotype with S-MBL below the median
forthisgenotype;low/aboveindicateslow
genotype with S-MBL above the median
for this genotype; and low/below indi-
cates low genotype with S-MBL below the
median for this genotype.
To illustrate time trends for cardio-
vascular outcome, Kaplan-Meier curves
were drawn using S-MBL less than or
greater than 1,000 g/l and the combina-
tion of geno- and phenotypes (high/
above, high/below, low/above, and low/
below) as strata. A log-rank test for trend
was applied to assess differences in event
patterns.
Cox proportional hazards regression
was used to test the prediction capacity of
dichotomized S-MBL (less than or greater
than 1,000 g/l), as well as of the combi-
nationofgeno-andphenotypes.Coxpro-
portional hazards regression models were
adjustedwiththesamecovariatesasthose
used in the regression analyses.
Two-tailed statistical tests were used
at a 5% signiﬁcance level. SAS (version
9.2) was used for all statistical analyses.
Ethical considerations
The study followed the recommenda-
tions of the Declaration of Helsinki, and
local ethics review boards approved the
protocol.Writteninformedconsentwas
obtained from all patients before
enrollment.
RESULTS— The baseline characteris-
tics of patients with S-MBL measured at
admission are presented in Table 1. S-
MBL varied between 10 and 6,382 g/l
(median 1,212 g/l; mean 1,666 g/l;
IQR 346–2,681 g/l). Patients (n  287)
with both an S-MBL and MBL2 genotype
had baseline characteristics and S-MBL
levelssimilartothoseofthetotalcohortof
patients with S-MBL available (n  387).
There were no signiﬁcant differences in
baseline characteristics between patients
with high (n  156) or low genotypes
(n  131) (Table 1). The median S-MBL
in patients with a high-coding genotype
was 2,658 g/l (IQR 1,715–3,829) com-
pared with 373 g/l (100–765) in those
with a low-coding genotype.
The genetic analyses revealed that
173 patients belonged to genotype AA
(60.3%), 104 to AO (36.2%), and 10 to
OO (3.5%). S-MBL differed signiﬁcantly
among patients with different genotypes
(Jonckheere-Terpstra test; P  0.001).
The respective medians and IQRs for the
three groups were AA 2,538 g/l (IQR
1,498–3,772), AO 384 g/l (130–702),
and OO 12 g/l (10–65).
There were no signiﬁcant differences
in S-MBL between men and women or
between patients with or without a his-
tory of myocardial infarction, heart fail-
ure,orhypertension(Table2).Moreover,
there were no signiﬁcant correlations be-
tween S-MBL and age, BMI, creatinine
clearance, glucose, and A1C at admission
(Spearman correlation).
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S-MBLandage,sex,BMI,creatinineclear-
ance, glucose, A1C, a history of myocar-
dial infarction, heart failure, and
hypertensionwasperformedseparatelyin
thedatasetwithallpatients(n387)and
in the geno- and phenotyped patients
(n  287). Only hypertension showed a
weak relationship (unadjusted P  0.05)
in patients with both geno- and pheno-
type available (data not shown).
Mortality and morbidity
Duringthefollow-upperiodof2.5(range
1.04–3.00) years, 35% of the total cohort
(n387)hadacardiovascularevent(Ta-
ble 3). The corresponding number in the
subgroup with both S-MBL and genotype
available (n  287) was 30.0%.
The predictive value of S-MBL for the
composite end point, its separate compo-
nents, and total mortality are shown in
Table 3. No model building was per-
formed, because S-MBL did not predict
theprimaryendpointoranycomponents
in the univariable analysis.
PatientswithS-MBL1,000g/lhad
lower event rates than those below that
level in a univariable Cox regression anal-
ysis (HR 0.68 [95% CI 0.48–0.95]; P 
0.02). This pattern remained after univa-
riableadjustmentsforage,admissionglu-
cose, BMI, sex, previous myocardial
infarction, and hypertension, but not
with adjustment for creatinine clearance,
A1C, or previous heart failure. However,
the dichotomized S-MBL did not predict
events (P  0.09) in a multiple Cox re-
gression model adjusting for signiﬁcant
confounders using a best subset selection
criterion (age, BMI, admission glucose,
creatinine clearance, and myocardial
infarction).
When we grouped the patients ac-
cording to their genotype and S-MBL
aboveorbelowthemedianfortheirgeno-
type (high/above [n  78], high/below
[n  78], low/above [n  65], and low/
below [n  66]), there was a signiﬁcant
trend among the four groups to predict
survival free from cardiovascular event
(log-rank test P  0.01) (Fig. 1). Using
thelow/belowgroupasareferenceinCox
regression analyses, patients with high/
above were the only group with a signiﬁ-
cantly lower event rate (HR  0.49 [95%
CI0.26–0.92];P0.03).Forpatientsin
the high/below and low/above groups
compared with low/below, the HRs were
0.66 ([0.37–1.17], P  0.15) and 0.89
([0.51–1.57], P  0.69), respectively.
These results remained after univariable
adjustments for admission glucose, A1C,
BMI, sex, previous myocardial infarction,
and hypertension, but not for age, creati-
nine clearance, or previous heart failure.
In a multiple Cox regression model ad-
justingforsigniﬁcantconfoundersusinga
best subset selection criterion (age, BMI,
Table 1—Baseline characteristics of all patients with S-MBL, of patients with both S-MBL and genotype, and of patients grouped according to
genotype (encoding high or low S-MBL concentration)
Variable All patients
Geno- and
phenotyped patients High genotype Low genotype
n 387 287 156 131
Age (years) 70.0 (61.1–77.1) 69.9 (60.7–76.7) 67.9 (60.4–75.7) 70.7 (61.1–77.1)
Male sex 264 (68) 194 (68) 107 (69) 87 (66)
BMI (kg/m
2) 28 (26–31) 28 (26–31) 28 (26–31) 28 (25–31)
Diabetes duration (years) 6.0 (2.0–14.0) 6.0 (1.0–14.0) 5.5 (0–13.0) 8.0 (2.0–14.5)
Blood pressure (mmHg)
Systolic 130 (120–150) 130 (120–150) 135 (120–150) 130 (115–145)
Diastolic 74 (65–85) 74 (63–85) 75 (64–85) 70 (60–80)
Previous medical history
Myocardial infarction 149 (39) 109 (38) 59 (38) 50 (38)
Angina pectoris 202 (52) 145 (51) 79 (51) 66 (50)
Heart failure 77 (20) 53 (19) 25 (16) 28 (21)
Hypertension 214 (55) 160 (56) 92 (59) 68 (52)
Hyperlipidemia 134 (35) 101 (35) 51 (33) 50 (38)
Current smoker 84 (22) 61 (21) 32 (21) 29 (22)
Medication before admission
Insulin 141 (36) 104 (36) 51 (33) 53 (40)
Metformin 102 (26) 73 (25) 35 (22) 38 (29)
Sulfonylurea 150 (39) 108 (38) 50 (32) 58 (44)
-Blocker 176 (46) 123 (43) 69 (45) 54 (41)
Aspirin 204 (53) 148 (52) 87 (56) 61 (47)
ACE inhibitor 122 (32) 94 (33) 53 (34) 41 (31)
Lipid-lowering 119 (31) 90 (31) 46 (30) 44 (34)
Biochemical analysis at admission
Blood glucose (mmol/l) 11.8 (9.2–14.9) 11.9 (9.5–14.9) 12.0 (9.3–15.1) 11.9 (9.6–14.9)
A1C (%) 7.1 (6.2–8.5) 7.1 (6.3–8.6) 7.0 (6.3–8.7) 7.3 (6.3–8.5)
Serum creatinine (mol/l) 91 (78–112) 89 (75–107) 88 (75–108) 90 (76–106)
Creatinine clearance (ml/min) 72 (49–92) 74 (51–96) 78 (52–97) 70 (49–95)
Serum cholesterol (mmol/l) 5.0 (4.2–5.8) 5.1 (4.4–5.9) 5.1 (4.6–5.9) 4.9 (4.2–6.0)
Serum triglycerides (mmol/l) 1.7 (1.2–2.6) 1.8 (1.2–2.7) 1.9 (1.2–2.7) 1.7 (1.1–2.7)
Data are n (%) or median (quartile 1–quartile 3). All variables refer to the time of hospital admission, unless otherwise stated.
Mellbin and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 2453creatinine clearance, and previous myo-
cardialinfarction),thepredictivecapacity
of the geno- and phenotype model was of
borderline signiﬁcance (P  0.07).
CONCLUSIONS — This study is the
ﬁrst to examine the distribution of MBL
geno- and phenotypes and the impact of
MBL on prognosis in patients with type 2
diabetes and myocardial infarction. The
patients had a MBL2 genotype distribu-
tion similar to that of the general popula-
tion and S-MBL did not contribute much
information on cardiovascular prognosis
beyond traditional risk markers. The re-
sults suggest that the combination of a
low geno- and phenotype is associated
with a poorer outcome, but they does not
explainwhetheraloworahighMBLlevel
is harmful in this patient group.
Inthepresentcohort,thedistribution
of MBL genotypes was similar to that in a
general European population (18,19),
with the majority of patients, 60%, be-
longing to the wild-type genotype (AA),
whereas the remainder had one or two
alleles with mutations (AO or OO). As
expected, the phenotypes were distrib-
uted with the highest S-MBL levels in pa-
tients belonging to the AA group and in
thoseclassiﬁedashavingahighgenotype,
i.e., also including information on poly-
morphisms in the promoter region (19).
The present S-MBL median of 1,212
g/l, with no sex difference, was higher
than that detected in outpatients with
type 2 diabetes and healthy control sub-
jects (median 666 and 728 g/l, respec-
tively) (17). One explanation for the
higher S-MBL in this cohort is that MBL
was measured at admission for AMI and
wastherebypossiblyinﬂuencedbystress.
In a study of patients with acute coronary
syndrome and matched control subjects,
patients had higher MBL than control
subjects (median 855 and 441 g/l; P 
0.0001) (5).
The present study does not resolve
the issues of whether a low or a high S-
MBL and which genotypes are harmful in
patientswithtype2diabetesandmyocar-
dialinfarction.Intheunadjustedanalysis,
S-MBL 1,000 g/l and the combination
of a low genotype with S-MBL below the
median for this genotype was associated
with a poorer outcome, but this ﬁnding
did not remain after adjustments.
Onelimitationofthepresentreportis
that patients with both geno- and pheno-
typesavailablehadalowereventratethan
that for the total cohort (Table 3). One
possible explanation is that genotypes
were measured at the time of hospital dis-
charge, thereby eliminating patients who
died in the hospital from the genotyped
subgroup. The results of the correlation
and regression analyses for continuous S-
MBL were, however, similar in the two
groups, suggesting that ﬁndings in the
genotypedgrouparerepresentative.Only
a larger study will be able to elucidate the
prognostic signiﬁcance of determining
MBL geno- and phenotypes.
Table 2—Differences between groups of patients stratiﬁed by dichotomous variables (Wil-
coxon Mann-Whitney test) and associations between continuous variables (Spearman rank
correlation) in all patients with S-MBL and in patients with both S-MBL and genotype available
Variable All patients
P
value
Geno- and
phenotyped
patients
P
value
n 387 287
Wilcoxon Mann-Whitney test S-MBL (g/1) S-MBL (g/1)
Sex
Male 1,357 (337–2,835) 0.44 1,555 (301–3,287) 0.19
Female 1,046 (347–2,394) 1,071 (371–2,336)
Previous myocardial
infarction
Yes 1,354 (346–2,568) 0.71 1,475 (303–2,878) 0.96
No 1,158 (347–2,836) 1,297 (346–2,930)
Previous heart failure
Yes 943 (241–2,100) 0.13 943 (239–2,392) 0.23
No 1,270 (373–2,860) 1,446 (386–2,930)
Previous hypertension
Yes 1,337 (386–2,836) 0.18 1,542 (407–2,941) 0.09
No 1,041 (234–2,605) 1,026 (177–2,778)
Spearman rank correlation Correlation
coefﬁcient
Correlation
coefﬁcient
Age 0.08 0.13 0.08 0.21
BMI 0.03 0.52 0.03 0.65
Biochemical analysis at
admission
Creatinine clearance 0.08 0.15 0.04 0.49
Glucose 0.06 0.22 0.05 0.43
A1C 0.01 0.84 0.04 0.48
Data are median (quartile 1–quartile 3) or correlation coefﬁcient.
Table 3—Number and proportion of events and the predictive value of S-MBL (Cox proportional hazards regression models) for respective
events in all patients with S-MBL and in patients with both S-MBL and genotype available
All patients Geno- and phenotyped patients
n (%) HR (95% CI) P value n (%) HR (95% CI) P value
n 387 287
Death 95 (24.6) 0.93 (0.84–1.04) 0.20 56 (19.5) 0.97 (0.85–1.12) 0.71
CV death 77 (19.9) 0.95 (0.85–1.08) 0.43 43 (15.0) 0.99 (0.84–1.16) 0.89
Reinfarction 58 (15.0) 0.95 (0.83–1.09) 0.45 41 (14.3) 0.93 (0.79–1.09) 0.35
Stroke 25 (6.5) 0.87 (0.72–1.06) 0.17 20 (7.0) 0.89 (0.71–1.10) 0.27
CV event 136 (35.1) 0.93 (0.85–1.01) 0.09 86 (30.0) 0.92 (0.82–1.02) 0.12
CV, cardiovascular.
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MBL or genotypes associated with a low
S-MBL to cardiovascular disease (7–
10,20). There are, however, reports of an
association between macrovascular dis-
ease and high MBL (5,6,21). These dis-
crepant ﬁndings may relate to differences
in study design, the composition of pa-
tient populations, and the type of events
studied. Pesonen et al. (5) noted that pa-
tients with acute coronary syndrome
had high S-MBL and genotypes, but this
was in comparison with healthy control
subjects. Furthermore, patients with
type 2 diabetes may react differently to
MBLthanthosewithouttype2diabetes.
In the study by Trendelenburg et al. (6)
few patients had diabetes. In studies
with a high proportion of patients with
diabetes, low S-MBL or low MBL geno-
types were related to a poor prognosis
(9,10).
The possible relationship between
low MBL and an increased risk of athero-
sclerosis may have several explanations.
Inastudycomprising2,176children,ho-
mozygosity for the MBL variant alleles
was associated with a greater impairment
in ﬂow-mediated dilation during infec-
tion compared with that in control sub-
jects without infection, suggesting that an
MBL gene-environment interaction, pos-
sibly occurring early in life, may have an
impact on the initiation and progression
of atherosclerosis (22).
The idea underlying the use of the
combination of genotype and MBL levels
beloworabovethemedianfortherespec-
tive genotype was to combine informa-
tionongeneticsusceptibilityandongoing
inﬂammation. The inability of this com-
bination to predict risk in the present co-
hort may be due to a lack of power, but it
also indicates that easily available factors
such as age and renal function are more
useful as clinical risk markers than
S-MBL.
MBL may play a different role in dif-
ferent settings, which limits its usefulness
as an overall risk marker or a treatment
target. However, before abandoning the
concept of MBL and the notion of the po-
tential importance of the innate immune
system for the progression of cardiovas-
cular diseases, it is important to look
furtherintodownstreamstepsofthecom-
plement cascade.
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